Aligos Therapeutics, Inc. (ALGS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$30.2M
Cash & Equivalents
$23.1M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$35M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06672900 | A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential ... | PHASE1 | Active Not Recruiting | 24 |
| NCT07342868 | Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Sub... | PHASE1 | Recruiting | 16 |
| NCT07342881 | Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Part... | PHASE1 | Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.